BMS's Yervoy awarded Prix Galien USA Discovery of the Decade
Award recognizes BMS for driving innovation in immuno-oncology.
Bristol-Myers Squibb (BMS) has received the Prix Galien USA Discovery of the Decade biotech award for Yervoy (ipilimumab), the company’s recombinant, human monoclonal antibody. In honour of the 10th anniversary of the Prix Galien awards and recognizing this decade as one of history's most productive for research, this special honour distinguishes BMS for its innovative discovery and development of Yervoy, which is now approved in more than 50 countries for treatment of unresectable or metastatic melanoma. The award is also a testament to BMS’s efforts to establish immuno-oncology as a transformational approach to treating a wide range of malignancies.
“We are honored to receive this special recognition for Yervoy, an agent that ushered in what can easily be described as a historical time in cancer research,” said Francis Cuss, chief scientific officer and executive vice president, Research & Development, BMS. “We are extremely proud that the highly distinguished selection committee recognized the extraordinary vision of our scientists and the strength of our research and development program, which includes a robust portfolio of early assets both in immuno-oncology and in targeted therapies.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.